NSCLC NON-SMALL CELL LUNG CANCER

This study is testing whether a new oral drug called daraxonrasib works better than standard chemotherapy (docetaxel) for people with advanced non-small cell lung cancer that has a specific genetic change (RAS mutation) and has stopped responding to initial treatments. About 420 …

This is a first-in-human study to find a safe dose and see how well a new drug called TGI-5 works, both by itself and combined with an existing immunotherapy (nivolumab). It is for adults with advanced solid tumors (like lung, colon, skin, or liver cancer) that have spread and no…

This study is testing whether a new type of immune cell therapy, called WAST cells, can help control advanced lung cancer when combined with standard chemotherapy. It's for patients whose cancer has continued to grow despite previous immunotherapy treatment. Researchers want to s…

This is a very early-stage study to test the safety of a new drug called GV20-0251 in adults with advanced solid tumors that have progressed despite standard treatments. The main goal is to find a safe dose by giving the drug to small groups of patients at different levels. It is…

This early-stage study is testing a new oral medication called YH42946 for people with advanced solid tumors that have specific genetic changes (HER2 or EGFR mutations). The trial aims to find the safest dose and see if the drug can shrink tumors in 161 patients who have run out …

This study is testing a new oral drug, PC14586 (rezatapopt), for people with advanced solid tumors that have a specific mutation in a gene called TP53 (Y220C). The main goals are to find a safe and effective dose and to see if the drug can shrink tumors. The trial is enrolling up…

This early-stage trial is testing a new radioactive drug called 177LuBetaBart in adults with advanced solid cancers that have stopped responding to standard treatments. The study aims to find a safe dose and see if the drug shows early signs of fighting tumors. Participants will …

This is the first study in people to test a new drug called NXP900 for advanced solid tumors. The main goals are to find a safe dose and see how the body processes the drug. The study will also look for early signs that the drug can shrink tumors, especially in cancers with speci…

This is an early-stage study to find a safe and effective dose of a new drug called IAM1363 for people with advanced cancers that have specific changes in a protein called HER2. The trial will enroll about 243 adults whose cancer has worsened after standard treatments, including …

This is the first-ever study in people for a new drug called EPI-326. It aims to find a safe dose and see how the body handles the drug in patients with advanced lung cancer (with a specific genetic change called EGFR mutation) or advanced head and neck cancer. The main goal is t…

This study is for people with stage II-IIIB non-small cell lung cancer who have had surgery after initial treatment with immunotherapy and chemotherapy. It tests whether using a sensitive blood test (called MRD) to detect tiny amounts of leftover cancer can help decide who needs …

This study is testing the safety of a new medical device called CAROL for treating small, early-stage lung cancer tumors. It involves patients who are already scheduled to have part of their lung surgically removed. Researchers will use the device to apply heat to the tumor befor…

This early-stage study is testing a new immunotherapy drug called OSE-279, both alone and in combination with another drug, for people with advanced solid tumors or lymphomas. The trial aims to find safe doses and see if these treatments can help control cancer growth. It's speci…

This study is testing a new type of cell therapy called A2B395 for adults with advanced solid tumors that have spread or returned. The therapy uses modified immune cells designed to specifically kill cancer cells while protecting the patient's healthy cells. The main goals are to…

This early-stage trial is testing a new oral medication called ALTA3263 in adults with advanced solid tumors that have specific KRAS mutations. The study aims to find a safe dose and see how the body processes the drug, while also checking for early signs that it might help contr…

This early-stage study is testing the safety and initial effects of a new oral medicine, PF-07799544, when taken with another drug, PF-07799933. It is for adults with advanced solid tumors, like melanoma or lung cancer, that have a specific genetic change called a BRAF V600 mutat…

This is the first study in people to test a new drug called XB010 for advanced solid tumors. The main goals are to find a safe dose and see how the body handles the drug, both by itself and when combined with another cancer therapy. It is for adults with certain advanced cancers …

This study is testing a new diagnostic platform called Cybrid that uses artificial intelligence to analyze small pieces of a patient's tumor. The goal is to see if this test can better predict which lung cancer patients will respond to immunotherapy drugs compared to current meth…

This study is testing a new diagnostic platform that uses artificial intelligence to analyze small pieces of a patient's tumor. The goal is to predict whether a patient's cancer will respond to immunotherapy drugs before they start treatment. Researchers will compare the AI's pre…

This study aims to understand how a single, high-dose radiation treatment affects the quality of life for people with inoperable lung tumors. Researchers will follow 190 patients who receive this one-session therapy, asking them to complete detailed questionnaires about their sym…

This study collects tumor tissue samples from cancer patients to research whether laboratory tests can predict which patients will respond to immunotherapy drugs. Researchers will analyze how live tumor samples react to immunotherapy treatments in the lab, then compare those resu…